TNMG Market Analysis

Overview

Fundamentals

P/E ratio
EPS (TTM)$-25.910.0% YoY
Profit margin-167.9%COMMUNICATION SERVICES
Market cap$1.6MMicro cap

Wall Street coverage

$14.00median target· current $214.30 (-93.5%)1 analyst

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E
PEG ratio
P/B
1.75
P/S (TTM)
0.03
EV/EBITDA

Profitability & growth

ROE (TTM)
-164.6%
Operating margin
-25.9%
Revenue growth YoY
5.7%
Dividend yield
Beta
0.78
Last earnings
Oct 6, 2025 · Estimate $0.00 · Reported $0.00
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About TNL Mediagene Ordinary Shares

TNL Mediagene Ordinary Shares is a forward-thinking biopharmaceutical company dedicated to innovating and commercializing advanced therapies for oncology and autoimmune diseases. With a robust pipeline enriched by state-of-the-art technologies and strategic partnerships, the company is well-positioned for substantial growth in the dynamic healthcare landscape. TNL Mediagene’s unwavering focus on scientific rigor and patient-centric solutions underscores its commitment to improving patient outcomes and tackling pressing health challenges, establishing its reputation as a significant player in…

Classification

Industry
Publishing
Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
23-2 MARUYAMACHO, TOKYO, JAPAN
Fiscal year end
December
Latest quarter
Mar 31, 2026
Market cap$1.6M
Shares outstanding$2.9M
52W high$12.76
52W low$0.50

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer